SRNG vs. AIM, PRME, IKT, PLX, ACHL, IZTC, ZIVO, BLUE, CRTX, and CYTH
Should you be buying Soaring Eagle Acquisition stock or one of its competitors? The main competitors of Soaring Eagle Acquisition include AIM ImmunoTech (AIM), Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Achilles Therapeutics (ACHL), Invizyne Technologies (IZTC), ZIVO Bioscience (ZIVO), bluebird bio (BLUE), Cortexyme (CRTX), and Cyclo Therapeutics (CYTH).
Soaring Eagle Acquisition vs. Its Competitors
Soaring Eagle Acquisition (NASDAQ:SRNG) and AIM ImmunoTech (NYSE:AIM) are both small-cap energy companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.
Soaring Eagle Acquisition has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Soaring Eagle Acquisition's return on equity of 0.00% beat AIM ImmunoTech's return on equity.
In the previous week, AIM ImmunoTech had 10 more articles in the media than Soaring Eagle Acquisition. MarketBeat recorded 10 mentions for AIM ImmunoTech and 0 mentions for Soaring Eagle Acquisition. Soaring Eagle Acquisition's average media sentiment score of 0.20 beat AIM ImmunoTech's score of 0.04 indicating that Soaring Eagle Acquisition is being referred to more favorably in the media.
AIM ImmunoTech received 59 more outperform votes than Soaring Eagle Acquisition when rated by MarketBeat users.
AIM ImmunoTech has a consensus price target of $275.00, suggesting a potential upside of 2,794.74%. Given AIM ImmunoTech's stronger consensus rating and higher possible upside, analysts plainly believe AIM ImmunoTech is more favorable than Soaring Eagle Acquisition.
Soaring Eagle Acquisition has higher earnings, but lower revenue than AIM ImmunoTech.
41.2% of Soaring Eagle Acquisition shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
AIM ImmunoTech beats Soaring Eagle Acquisition on 7 of the 12 factors compared between the two stocks.
Get Soaring Eagle Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRNG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SRNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soaring Eagle Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:SRNG) was last updated on 6/24/2025 by MarketBeat.com Staff
Buy SRNG Stock Free SRNG Stock Alerts